You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Biological: CART 22

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma Trial in Philadelphia (Autologous, humanized anti-CD22 CAR

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B Lineage Lymphoblastic Lymphoma
  • Autologous, humanized anti-CD22 CAR T cell therapy (CART22-65s)
  • Autologous, humanized anti-CD19 CAR T cell therapy (huCART19)
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 25, 2023

Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Leukemia in Children Trial in Singapore (Phase

Recruiting
  • Lymphoblastic Leukemia
  • +4 more
  • Phase I
  • Phase II
  • Singapore, Singapore
    KK Women's and Children's hospital
Jun 20, 2022

Hairy Cell Leukemia, Hairy Cell Leukemia Variant Trial run by the NCI (CD22CART cell infusion)

Recruiting
  • Hairy Cell Leukemia
  • Hairy Cell Leukemia Variant
  • CD22CART cell infusion
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 25, 2023

Chemo Resistant Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia Trial in Philadelphia (CART22-65s cells,

Active, not recruiting
  • Chemotherapy Resistant Acute Lymphoblastic Leukemia
  • Refractory Acute Lymphoblastic Leukemia
  • CART22-65s cells
  • huCART19 Cells
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 18, 2022

Therapy Related Leukemia Trial in Guangdong (Sequential Treatment With different CART)

Recruiting
  • Therapy Related Leukemia
  • Sequential Treatment With different CART
  • Guangdong, Guangdong, China
    Southern Medical University Zhujiang Hospital
Aug 9, 2021

Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma Trial in Suzhou (CD19/22 CART, Tislelizumab)

Unknown status
  • Relapsed Non Hodgkin Lymphoma
  • Refractory Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jul 30, 2021

B Cell Leukemias, B Cell Lymphomas Trial in Philadelphia (CART22 cells transduced with a lentiviral vector to express anti-CD22

Recruiting
  • B Cell Leukemias
  • B Cell Lymphomas
  • CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB
  • Philadelphia, Pennsylvania
    Children's Hospital of Philadelphia
Jan 19, 2022

Breast Cancer Trial in Derby (One-stage immediate breast reconstruction)

Not yet recruiting
  • Breast Cancer
  • One-stage immediate breast reconstruction
  • Derby, United Kingdom
    University Hospitals of Derby and Burton NHS Foundation Trust
Jul 4, 2022

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Leukemia, Lymphoma Trial in Beijing (Anti-CD22-CAR-transduced T cells)

Unknown status
  • Leukemia
  • Lymphoma
  • Anti-CD22-CAR-transduced T cells
  • Beijing, Beijing, China
    Fengtai District
Feb 6, 2021

HER2-negative Breast Cancer Trial in Georgia, Mexico, United Kingdom (AZD9833)

Recruiting
  • HER2-negative Breast Cancer
  • Batumi, Georgia
  • +18 more
Jan 13, 2023

Multiple Myeloma Trial in Tianjin (anti-BCMA CAR-T, Selinexor-VRD)

Recruiting
  • Multiple Myeloma
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 12, 2023

Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,

Not yet recruiting
  • Bladder Squamous Cell Carcinoma
  • +10 more
  • Biospecimen Collection
  • +5 more
  • Atlanta, Georgia
  • +3 more
Feb 20, 2023

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
May 13, 2023

T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Angioimmunoblastic T-cell Lymphoma Trial in Saint Louis (WU-CART-007)

Not yet recruiting
  • T-Cell Non-Hodgkin Lymphoma
  • +14 more
  • WU-CART-007
  • Saint Louis, Missouri
    Washington University School of Medicine
Jan 17, 2023

Adult B Acute Lymphoblastic Leukemia Trial in Shijiazhuang (CD19 CAR-T, CD22 CAR-T, CD19+CD22 CAR-T)

Recruiting
  • Adult B Acute Lymphoblastic Leukemia
  • CD19 CAR-T
  • +4 more
  • Shijiazhuang, Hebei, China
    No.2 Hospital of Hebei Medical University
Nov 11, 2020

DLBCL, Grade 3b Follicular Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial (biological, procedure, drug,

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • +6 more
  • Axicabtagene Ciloleucel
  • +10 more
  • (no location specified)
Jan 13, 2023

Digestive Tumor Trial (TM4SF1-positive chimeric antigen receptor T-cell therapy)

Not yet recruiting
  • Digestive Tumor
  • TM4SF1-positive chimeric antigen receptor T-cell therapy
  • (no location specified)
Dec 21, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma Trial

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • +5 more
  • Biospecimen Collection
  • +4 more
  • (no location specified)
Oct 28, 2022

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Multiple Myeloma Trial in Boston, Milwaukee (CART-ddBCMA)

Not yet recruiting
  • Multiple Myeloma
  • CART-ddBCMA
  • Boston, Massachusetts
  • +1 more
Jul 7, 2022

Multiple Myeloma Trial in Philadelphia (CART-19 cells)

Terminated
Has Results
  • Multiple Myeloma
  • CART-19 cells
  • Philadelphia, Pennsylvania
    Abramson Cancer Center of the University of Pennsylvania
Jan 4, 2023

Castrate-Resistant Prostate Cancer Trial in Shanghai (LIGHT-PSMA-CART cells)

Suspended
  • Castrate-Resistant Prostate Cancer
  • LIGHT-PSMA-CART cells
  • Shanghai, Shanghai, China
    Changhai Hospital
Jan 25, 2023

HIV Infection Primary Trial in Badalona (Dasatinib 70 mg, Placebo)

Not yet recruiting
  • HIV Infection Primary
  • Dasatinib 70 mg
  • Placebo
  • Badalona, Barcelona, Spain
    Hospital Universitari Germans Trias i Pujol
Mar 9, 2023

Plasma Cell Leukemia Trial in Tianjin (anti-BCMA CAR-T, VRD-based regimen)

Recruiting
  • Plasma Cell Leukemia
  • anti-BCMA CAR-T
  • VRD-based regimen
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
Aug 4, 2023